loading page

HALP Score and Albumin Levels in Men with Prostate Cancer and Benign Prostate Hyperplasia
  • +1
  • Coskun Kaya,
  • Selahattin Caliskan,
  • Mustafa Sungur,
  • Cemil Aydın
Coskun Kaya
Eskisehir State Hospital, Department of Urology
Author Profile
Selahattin Caliskan
Reyap Hospital, Department of Urology
Author Profile
Mustafa Sungur
Eskişehir State Hospital
Author Profile
Cemil Aydın
Faculty of Medicine, Hitit University, Department of Urology
Author Profile

Abstract

Aims: To evaluate the diagnostic significance of the novel index combining preoperative hemoglobin, albumin levels, lymphocyte and platelet counts (HALP) in prostate cancer (PCa) patients. Methods: Between January 1, 2015 to December 31, 2018 at the Hitit University Erol Olçok Education and Research Hospital 225 patients who had undergone transrectal ultrasound guided prostate biopsy or prostate surgery were analyzed retrospectively. A total of patients; 155 had benign prostate hyperplasia (group 1) and 70 had PCa (group 2). The preoperative serum levels of hemoglobin, albumin, lymphocyte counts, and platelet counts were recorded. The HALP scores and the sub parameters of this index for each of the two groups were compared. Results: The total Prostate Specific Antigen (PSA), albumin and lymphocyte differences between the groups were statistically significant (p=0.0002, p=0.0001, p= 0.005). The median value of HALP scores in Group 1 and 2 were 49.43 and 51.2 respectively, and this was not statistically significant between groups (p=0.737). The HALP score had the least Area Under Curve (AUC) value compared to the others (0.514). the AUC of Albumin was larger than PSA for diagnostic efficacy in PCa patients (0.696-0.656). However, albumin levels were statistically significant compared to platelet count and the HALP score (p=0.0033, p=0.0068), except PSA and lymphocyte (p=0.4580, p=0.1717). Conclusion:Further prospective clinical studies that include more patients from multiple centers are needed to show the diagnostic role of the HALP score and its compounds on the patients with PCa.

Peer review status:UNDER REVIEW

25 Jul 2020Submitted to International Journal of Clinical Practice
28 Jul 2020Submission Checks Completed
28 Jul 2020Assigned to Editor
31 Aug 2020Reviewer(s) Assigned
09 Sep 2020Review(s) Completed, Editorial Evaluation Pending
09 Sep 20201st Revision Received
10 Sep 2020Reviewer(s) Assigned
10 Sep 2020Submission Checks Completed
10 Sep 2020Assigned to Editor
24 Sep 2020Review(s) Completed, Editorial Evaluation Pending